Abstract
There are currently two commercially available valves in the United States for use in the pulmonic position, the Melody valve (Medtronic Inc., Minneapolis, MN) and the Edwards SAPIEN XT valve (Edwards Lifesciences LLC, Irvine, CA). The initial use of the SAPIEN was as a percutaneous substitute to surgical valve replacement in the aortic position; however, it has emerged as an alternative to the Melody valve in the pulmonic position and has been used successfully in the right ventricular (RV) to pulmonary artery (PA) conduits since 2005. In March 2016, the SAPIEN XT (second generation of the Edwards SAPIEN transcatheter heart valve) (Figs. 27.1, 27.2, and 27.3) gained the approval of the US Food and Drug Administration (FDA) for use in dysfunctional RV to PA conduits.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Holoshitz, N., Mann, G., Hijazi, Z.M. (2019). Edwards SAPIEN XT Valve Implantation in the Pulmonary Position. In: Butera, G., Chessa, M., Eicken, A., Thomson, J.D. (eds) Atlas of Cardiac Catheterization for Congenital Heart Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-72443-0_27
Download citation
DOI: https://doi.org/10.1007/978-3-319-72443-0_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-72442-3
Online ISBN: 978-3-319-72443-0
eBook Packages: MedicineMedicine (R0)